PTC
NBIX icon

Philadelphia Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Philadelphia Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.08M Buy
30,135
+2,037
+7% +$302K 0.33% 56
2026
Q1 		$3.7M Sell
28,098
-662
-2% -$87.8K 0.26% 64
2025
Q4 		$4.08M Sell
28,760
-900
-3% -$130K 0.28% 62
2025
Q3 		$4.16M Sell
29,660
-5,000
-14% -$677K 0.29% 61
2025
Q2 		$4.36M Hold
34,660
– – 0.33% 55
2025
Q1 		$3.83M Sell
34,660
-1,750
-5% -$222K 0.33% 60
2024
Q4 		$4.97M Buy
36,410
+29,685
+441% +$3.67M 0.36% 58
2024
Q3 		$775K Buy
+6,725
New +$922K 0.06% 133

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Philadelphia Trust Company's NBIX Position: Q2 2026 in Review

Philadelphia Trust Company increased its Neurocrine Biosciences (NBIX) stake by 7.2% in Q2 2026, buying an estimated $302K and bringing the position to 30,135 shares worth $5.08M. The position accounts for 0.33% of the portfolio, ranked #56.

Philadelphia Trust Company first reported a position in NBIX in Q3 2024 and has held it in 8 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Philadelphia Trust Company held 30,135 shares of Neurocrine Biosciences worth $5.08M as of Q2 2026.
  • Philadelphia Trust Company bought 2,037 Neurocrine Biosciences shares in Q2 2026, an estimated $302K.
  • Neurocrine Biosciences made up 0.33% of Philadelphia Trust Company's portfolio in Q2 2026, its #56 holding.
  • Philadelphia Trust Company first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 8 quarters since.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Philadelphia Trust Company's 13F filing for Q2 2026, filed 10 Aug 2026.